development aspects
Vaxcyte Advances 31-Valent Pneumococcal Vaccine to Phase 3 Trials Following Positive Phase 1/2 Results
Vaxcyte, VAX-31, Pneumococcal Vaccine, Phase 3 Trials, Invasive Pneumococcal Disease, Vaccine Development
UCLA Receives $120 Million Donation for Immunology Research and Vaccine Development
UCLA, immunology research, vaccine development, $120 million donation, Gary Michelson, Alya Michelson, California Institute for Immunology and Immunotherapy
BioMarin Appoints New R&D and Business Development Leaders
BioMarin, R&D, Business Development, Leadership, Greg Friberg, James Sabry, Hank Fuchs
Arrowhead Shifts Focus to Obesity Development After Heart Disease Drug Clearance
Arrowhead, obesity development, heart disease drug, biotech, pharmaceuticals, clinical-stage candidates, preclinical assets
Evotec Announces 400 Job Cuts Amid Market Challenges
Evotec, job cuts, market challenges, restructuring, drug discovery, contract development, manufacturing
Lilly Opens State-of-the-Art Research and Development Center in Boston
Lilly, Boston, research and development, genetics research, biotech incubator, East Coast hub
Aeterna Zentaris Rebrands as COSCIENS Biopharma: A New Era in Biopharmaceuticals
Aeterna Zentaris, COSCIENS Biopharma, biopharmaceuticals, rebranding, name change, therapeutic development, diagnostic tests, Macrilen, adult growth hormone deficiency
Valneva Invests $10M in LimmaTech for Clinical-Stage Shigella Vaccine
Valneva, LimmaTech, Shigella vaccine, clinical-stage, biotech, pharmaceuticals, vaccine development
GSK Abandons Phase 2 HPV Vaccine Due to Lack of Best-in-Class Potential
GSK, HPV vaccine, phase 2, best-in-class potential, vaccine development
Novartis to Wind Down San Diego Technical Research and Development Site by Mid-2025
Novartis, San Diego, Technical Research and Development, Site Closure, Layoffs, Restructuring